Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma
✍ Scribed by Paweł Sedlaczek; Irena Frydecka; Marian Gabryś; Arie van Dalen; Roland Einarsson; Antonina Harłozińska
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 131 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
The serum markers ca125, tissue polypeptide specific antigen (tps), and soluble interleukin-2 receptor alpha (sil-2ralpha) concentrations were determined in sera, cyst, and ascitic fluids from patients with malignant and benign ovarian neoplasms.
Methods:
Ca125, tps, and sil-2ralpha concentrations were measured in sera, cyst, and ascitic fluids by immunoassays in 67 patients with carcinoma and in 32 patients with benign ovarian neoplasms.
Results:
Ca125, tps, and sil-2ralpha levels were elevated significantly in sera from patients who had ovarian carcinoma compared with patients who had benign neoplasms (p < 0.001). patients who had international federation of gynecology and obstetrics (figo) stage iii-iv disease had significantly higher serum levels for the markers studied compared with patients who had figo stage i-ii disease (p < 0.001 for ca125; p = 0.02 for tps and sil-2ralpha). concurrent measurement of ca125 and sil-2ralpha in sera identified 100% of ovarian carcinomas in figo stage i-ii. all patients with carcinoma demonstrated markedly higher levels of ca125 and tps for both cyst and ascites compared with corresponding sera (p < 0.001). the level of sil-2ralpha was higher statistically in ascitic fluid compared with the level in serum (p < 0.001); however, its values in sera and cyst fluids were comparable. in ascitic fluid, the ca125 level was significantly higher in patients who had figo stage iii-iv disease compared with patients who had figo stage i-ii disease (p = 0.002), whereas such correlations were not found for tps or sil-2ralpha. in cyst fluids, the levels of all studied markers were independent of the figo stage. in cyst fluids from patients with benign ovarian neoplasms, tps and sil-2ralpha levels were significantly lower compared with the levels in patients with ovarian carcinoma (p < 0.001), whereas the values of ca125 were overlapping. ca125 and tps concentrations were higher in cyst fluids compared with corresponding sera, whereas sil-2ralpha levels were comparable and low in cyst fluids and in the circulation of patients with benign neoplasms.
Conclusions:
In patients with ovarian carcinoma, tps and ca125 concentrations were significantly higher in the place of their generation compared with the concentrations in blood circulation. sil-2ralpha values were higher in ascites compared with the values in corresponding sera, and its concentrations in sera and cyst fluids were comparable. the assessment of serum sil-2ralpha levels showed potential complementary value to ca125 for the detection of ovarian carcinoma in early figo stages; however, a 9% false positive rate limited the significance of cumulative value for a combination of these circulating markers.